Patients’ Perspectives on Psychiatric Pharmacogenetic Testing
Introduction There is growing interest to adopt pharmacogenetic (PGx) testing in psychiatric medicine, despite mixed views regarding its clinical utility. Nevertheless, providers are utilizing PGx testing among patients with mental health disorders. This study sought to assess genotyped patients’ perspectives and experiences with psychiatric PGx testing.
Methods Individual semi-structured interviews were conducted among patients with depression who had undergone psychiatric PGx testing. The audio-recorded interviews were transcribed and analyzed inductively and deductively for salient themes.
Results Twenty patients (100% Caucasian, 60% female, mean age 39±18 years) were interviewed. The majority of the PGx tests were provider-initiated for patients who failed multiple pharmacotherapies (50%) and/or had medication intolerances (45%). Patients’ pre-testing expectations ranged from hopefulness to indifference to skepticism. Their post-testing experiences varied from optimism to disappointment, with the perceived value of the test influenced by the results and cost of the test.
Discussion Genotyped patients had mixed perspectives, expectations, and experiences with psychiatric PGx testing. Their perceived value of the test was influenced by the test outcomes and its cost.
Received: 10 December 2019
Received: 18 March 2020
Accepted: 11 May 2020
24 June 2020 (online)
© 2020. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
- 1 Kessler RC, Berglund P, Demler O. et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 593-602
- 2 Gartlehner G, Hansen RA, Morgan LC. et al. Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: An updated meta-analysis. Ann Intern Med 2011; 155: 772-785
- 3 Hansen RA, Gartlehner G, Lohr KN. et al. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med 2005; 143: 415-426
- 4 Trivedi MH, Rush AJ, Wisniewski SR. et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. Am J Psychiatry 2006; 163: 28-40
- 5 Drozda K, Muller DJ, Bishop JR. Pharmacogenomic testing for neuropsychiatric drugs: Current status of drug labeling, guidelines for using genetic information, and test options. Pharmacotherapy 2014; 34: 166-184
- 6 Eap CB. Personalized prescribing: A new medical model for clinical implementation of psychotropic drugs. Dialogues Clin Neurosci 2016; 18: 313-322
- 7 Eum S, Lee AM, Bishop JR. Pharmacogenetic tests for antipsychotic medications: Clinical implications and considerations. Dialogues Clin Neurosci 2016; 18: 323-337
- 8 Tansey KE, Guipponi M, Hu X. et al. Contribution of common genetic variants to antidepressant response. Biol Psychiatry 2013; 73: 679-682
- 9 Hicks JK, Bishop JR, Sangkuhl K. et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther 2015; 98: 127-134
- 10 Hicks JK, Sangkuhl K, Swen JJ. et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther 2017; 102: 37-44
- 11 Relling MV, Klein TE. CPIC: clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clin Pharmacol Ther 2011; 89: 464-467
- 12 Swen JJ, Nijenhuis M, de Boer A. et al. Pharmacogenetics: from bench to byte—an update of guidelines. Clin Pharmacol Ther 2011; 89: 662-673
- 13 International Society for Psychiatric Genetics (ISPG). Genetic testing statement: A statement from the international society of psychiatric genetics. 2019; https://ispg.net/genetic-testing-statement/
- 14 Bousman CA, Dunlop BW. Genotype, phenotype, and medication recommendation agreement among commercial pharmacogenetic-based decision support tools. Pharmacogenomics J 2018; 18: 613-622
- 15 Bousman CA, Hopwood M. Commercial pharmacogenetic-based decision-support tools in psychiatry. Lancet Psychiatry 2016; 3: 585-590
- 16 Dunnenberger HM, Biszewski M, Bell GC. et al. Implementation of a multidisciplinary pharmacogenomics clinic in a community health system. Am J Health Syst Pharm 2016; 73: 1956-1966
- 17 Haga SB, O’Daniel JM, Tindall GM. et al. Survey of US public attitudes toward pharmacogenetic testing. Pharmacogenomics J 2012; 12: 197-204
- 18 Lemke AA, Hulick PJ, Wake DT. et al. Patient perspectives following pharmacogenomics results disclosure in an integrated health system. Pharmacogenomics 2018; 19: 321-331
- 19 Mukherjee C, Sweet KM, Luzum JA. et al. Clinical pharmacogenomics: patient perspectives of pharmacogenomic testing and the incidence of actionable test results in a chronic disease cohort. Per Med 2017; 14: 383-388
- 20 Rogausch A, Prause D, Schallenberg A. et al. Patients’ and physicians’ perspectives on pharmacogenetic testing. Pharmacogenomics 2006; 7: 49-59
- 21 Trinidad SB, Coffin TB, Fullerton SM. et al. “Getting off the Bus Closer to Your Destination”: Patients’ Views about Pharmacogenetic Testing. Perm J 2015; 19: 21-27
- 22 Deininger KM, Tran JN, Tsunoda SM. et al. Stakeholder perspectives of the clinical utility of pharmacogenomic testing in solid organ transplantation. Pharmacogenomics 2019; DOI: 10.2217/pgs-2019-0129.
- 23 Hoop JG, Lapid MI, Paulson RM. et al. Clinical and ethical considerations in pharmacogenetic testing: views of physicians in 3 “early adopting” departments of psychiatry. J Clin Psychiatry 2010; 71: 745-753
- 24 Deininger KM, Page RL, Lee YM. et al. Non-interventional cardiologists‘ perspectives on the role of pharmacogenomic testing in cardiovascular medicine. Per Med 2019; 16: 123-132
- 25 Frigon MP, Blackburn ME, Dubois-Bouchard C. et al. Pharmacogenetic testing in primary care practice: opinions of physicians, pharmacists and patients. Pharmacogenomics 2019; 20: 589-598
- 26 Chan CY, Chua BY, Subramaniam M. et al. Clinicians‘ perceptions of pharmacogenomics use in psychiatry. Pharmacogenomics 2017; 18: 531-538
- 27 Bousman CA, Zierhut H, Muller DJ. Navigating the labyrinth of pharmacogenetic testing: A guide to test selection. Clin Pharmacol Ther 2019; 106: 309-312
- 28 Inc UHS United healthcare commercial medical policy: Pharmacogenetic testing. (10/01/2019), Available: https://www.uhcprovider.com/content/dam/provider/docs/public/policies/comm-medical-drug/pharmacogenetic-testing.pdf
- 29 Haga SB, O’Daniel JM, Tindall GM. et al. Survey of US public attitudes toward pharmacogenetic testing. The Pharmacogenomics J 2012; 12: 197-204
- 30 Lee YM, McKillip RP, Borden BA. et al. Assessment of patient perceptions of genomic testing to inform pharmacogenomic implementation. Pharmacogenet Genomics 2017; 27: 179-189